Case study of multi-drug resistant woman receiving newer antiretroviral drugs in pregnancy

HIV Treat Bull - 2008 July-August;9(7/8):

Polly Clayden, HIV i-Base

A poster from Furco and coworkers from Northwick Park Hospital, Harrow, St Mary’s Hospital, London and Chelsea and Westminster Hospital, London reported a case study of a multi-drug resistant HIV-positive pregnant woman receiving a combination of newer antiretroviral drugs.

This patient was a 38-year-old African woman, pregnant with twins, who presented with a viral load of 4,660 copies/mL and CD4 count 471 cells/mm³) in early trimester.

She had previously been treated with different combinations of NRTIs (5), NNRTIs (2) and protease inhibitors (2). Genotypic sequencing showed the following mutations - RT: D67N, V118I/V, M184V, Y188L, L210W, T215Y; protease: L10I, I13V, G16E, K20I, M36I, M46I, I47V, F53L, I54V, D60E, D63T, H69K, I84V, L89M. A confirmatory phenotypic test showed high-level antiretroviral resistance.

At 25 weeks gestation, she received a combination of tenofovir/emtricitabine, darunavir/ritonavir, etravirine and enfuvirtide. After 4 weeks her viral load was undetectable (<50 copies/mL).

PK studies for enfuvirtide, etravirine and darunavir were performed and all drug concentrations were within the expected therapeutic ranges.

At 34 weeks, her viral load was still undetectable and she delivered two HIV negative infants by caesarean section.

The infants received ARV prophylaxis with enfuvirtide, nevirapine and ddI. The investigators noted that enfurvirtide was undetectable and darunavir/ritonavir and etravirine were detectable in cord blood. The infants’ adverse events included injection site reactions, hypertriglyceridaemia, anaemia, transient hypereosinophilia and raised alanine transferase.

Reference:

Furco A, Gosrani B, Nicholas S et al. Use of newer antiretroviral (ARV) drugs (darunavir, etravirine and enfuvirtide) in HIV-positive pregnant woman with pan-class resistance failure. HIV Med 2008; 9(Suppl. 1):22 (abstract no. P60).

2008-07-10
IB080907-03c

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.